FDA Clears New, Safer Formulation of Ranitidine After Full Safety Evaluation

Published On 2025-12-01 05:00 GMT | Update On 2025-12-01 10:17 GMT

The U.S. Food and Drug Administration has approved reformulated ranitidine tablets, marking the return of this important acid-reducing medication to the U.S. market after a five-year absence. The approval follows extensive safety testing and manufacturing improvements that address previous concerns about N-nitrosodimethylamine (NDMA) impurity formation during the product’s shelf-life.

Ranitidine, an H2 receptor antagonist, is widely used to treat conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome.

Clinical Considerations: Healthcare providers and patients should be aware that the reformulated ranitidine maintains the same therapeutic effectiveness as previously approved products. Patients currently using alternative H2 blockers or proton pump inhibitors should consult their healthcare providers before switching medications. Approved products will include updated labeling with storage and handling instructions. Patients and healthcare providers should consider the new storage conditions for the safe and effective use of the product which include:

• Keep Ranitidine Tablets in the original container (bottle) and protect from moisture.

• After the first opening of the bottle, discard unused tablets after 3 months (90 days), or by the expiration date on the bottle, whichever is sooner.

• If more than one bottle is dispensed, open only one bottle at a time. Store additional bottles without opening until needed for dosing.

• At the time of dosing, remove one tablet from the bottle. Immediately close the bottle, secure the cap, and keep the bottle tightly closed.

• Keep the desiccant in the bottle.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

FDA Clears New, Safer Formulation of Ranitidine After Full Safety Evaluation

Similar News

Apixaban Raises GI Bleeding Risk in Subclinical AF Compared to Aspirin: JAMA

Mild Pancreatic Duct Dilatation Linked to Pancreatic Cancer Risk: Study

Proton Pump Inhibitors Linked to Worse Outcomes in Breast Cancer Patients: Study

Chronic Cough Reported in Patients Using GLP-1 Drugs, Study Finds

AI Detects Pancreatic Cancer More Accurately Than Radiologists, Finds Research

Chronic Hepatitis C Linked to Higher Pancreatic Cancer Risk: JAMA

Red & Processed Meat Swap with Legumes May Reduce Gallbladder Disease Risk: Study